The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab

Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis

(2015) H Chiu et al.   ACTA DERMATO-VENEREOLOGICA

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers

(2015) Tzu-Chang Wang et al.   Dermatologica Sinica

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

(2015) Denis Jullien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Systemic Therapies for Psoriasis: An Evidence-Based Update

(2014) Laura F. Sandoval et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis

(2014) Der-Yuan Chen et al.   ANNALS OF THE RHEUMATIC DISEASES

Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis

(2014) H.-Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

(2013) H.-Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Antidrug antibodies in psoriasis: a systematic review

(2013) L. Hsu et al.   BRITISH JOURNAL OF DERMATOLOGY

Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

(2013) Stef P. Menting et al.   JAMA Dermatology

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

(2012) T.-F. Tsai et al.   BRITISH JOURNAL OF DERMATOLOGY

Cytokine-Based Therapy in Psoriasis

(2012) Anupam Mitra et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

T helper type 17 in psoriasis: From basic immunology to clinical practice

(2012) Hsien-Yi Chiu et al.   Dermatologica Sinica

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis

(2011) H.Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Ustekinumab in clinical practice: response depends on dose and previous treatment

(2011) V. Ruiz Salas et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis

(2011) H.-Y. Chiu et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

(2010) Lidian L. A. Lecluse et al.   ARCHIVES OF DERMATOLOGY

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

(2010) Pauline A. van Schouwenburg et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

(2009) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET